Skip to content
Politically.com Search all
Menu

2026 · 2nd Quarter (Apr 1 - June 30)

ASSOCIATION OF ACCESSIBLE MEDICINES

Filed by MEHLMAN CONSULTING, INC..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 17, 2026
Income
$60,000.00
Expenses
Not reported
Filing UUID
719e68e6-66e9-4773-8ee5-e2bb3a1f530c
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Issues related to generic medicines.

HCR · Health Issues

Issues related to generic and biosimilar medications.

PHA · Pharmacy

Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; Country of origin labeling.

Literal federal measure citations: S. 1040, H.R. 5526, S. 1954, H.R. 3269, S. 43, H.R. 1843, S. 1302

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.